Rad Laboratories ( (BIO) ) has provided an announcement. On October 29, 2025, Bio-Rad Laboratories reported its financial results for the third quarter ended September 30, 2025. Despite challenges in ...

Bio-Rad Laboratories Inc. (BIO.B) on Wednesday reported a third-quarter loss of $341.9 million, after reporting a profit in the same period a ...

Bio-Rad Laboratories, Inc. (BIO) is scheduled to announce Q3 earnings results on Wednesday, October 29th, after market close. The consensus EPS Estimate is $1.9 ...

The outlook for full year 2025 remains unchanged at flat to 1% currency-neutral revenue growth, consistent with the Q2 update. Margins guidance is also unchanged. Q3 reported a slight revenue and ...

Bio-Rad Laboratories Inc. (NYSE:BIO) released its second quarter 2025 financial results on July 31, 2025, showing modest revenue growth despite challenging market conditions. The company’s stock ...

In September 2025, BioWorld recorded 230 clinical trial updates spanning phases I through III, up sharply from 95 in August, 140 in July and just below 254 in June. Among these, 22 phase III trials ...

UNHCR and its partners actively collect and analyze socioeconomic data to inform sustainable responses that enhance protection, inclusion and solutions for forcibly displaced persons. Our efforts are ...

Preclinical data for CLYM116, anti-APRIL monoclonal antibody, highlight favorable pharmacokinetic and pharmacodynamic profile, supporting development for IgA nephropathy (IgAN) Long-term follow-up ...

Investing.com - Guggenheim has raised its price target on Adicet Bio Inc. (NASDAQ:ACET) to $8.00 from $7.00 while maintaining a Buy rating following impressive clinical data from the company’s lupus ...

Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the ...

-Clinical data to date supports a potentially transformational approach to treating autoimmune diseases with an off-the-shelf, one-time therapy- -As of the August 31, 2025 data cut-off date, all seven ...

EINPresswire/ -- Bio Implant Allograft And Xenograft Market Growth Forecast: What To Expect By 2025? In the last few years, there has been significant growth in the bio implant allograft and xenograft ...